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INTRODUCTION
Osteoporosis is defined as a skeletal disorder
characterized by compromised bone strength pre-
disposing a person to an increased risk of fracture
(1). Osteoporotic fractures are one of significant
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complications and an increasing health care bur-
den in osteoporotic patients. As the population of
elderly people increases, the incidence of osteo-
porotic fractures is expected to dramatically rise.
At present, large number of postmenopausal women
in Japan are at high risk for osteoporosis and its
associated fractures, which is an issue of clinical
importance. Therefore, in the treatment of osteo-
porosis, prevention of fractures is undoubtedly a
major goal. Smith showed that bone mineral density
(BMD) was accounted for approximately 75-80% of
the variance in the bone strength (2). It is an un-
doubted fact that BMD is one of the important de-
terminants of bone strength.
The purpose of this study was to clarify the dif-
ference of therapeutic effects of regional BMD and
markers of bone mineral metabolism between one-
year treatment of alendronate and that of alfacalcidol.
Alendronate is a second-generation aminobisphos-
phonate. Bisphosphonate is an antiresorptive agent
of bone and it increases BMD and bone mineral
content resulting from inhibition of osteoclast-
mediated bone resorption (3, 4), leading to pre-
vention of osteoporotic fractures, hip fractures (5)
and vertebral fractures (6). Alfacalcidol, 1 alfa-
hydroxyvitamin D3, is a prodrug of calcitriol, and is
one of active vitamin D analog. Alfacalcidol has been
widely used in the treatment of osteoporosis in
Japan. Alfacalcidol stimulates intestinal calcium ab-
sorption, increases urinary Ca excretion and serum
Ca levels, and suppresses parathyroid hormone
secretion (5). Alfacalcidol is effective to increase
BMD and reduces rate of vertebral fracture (7) or
hip fracture (8).
MATERIALS AND METHODS
One hundred and three Japanese women suffer-
ing from primary osteoporosis without osteoporotic
fractures, aged 55 to 81 years, were divided into
two groups : women treated orally with alendro-
nate for one year (5mg/day) (alendronate group,
n=41) and women treated orally with alfacalcidol
for one year (0.5μg/day) (alfacalcidol group, n=62).
In the alendronate group, 35 of 41 women com-
pleted one-year treatment of alendronate. In con-
trast, 57 of 62 women in the alfacalcidol group
completed one-year treatment of alfacalcidol. All
the women had no osteoporotic fractures, no renal
injury, no disease of the alimentary tract, no osteo-
malacia, and no primary or secondary neoplastic
bone disease. None of them had received treat-
ments affecting bone metabolism. All the women
are allowed to continue their usual diets. Table 1
showed pre-treatment values of body mass index
(BMI), age, L2-4BMD, total body BMD. No sig-
nificant differences were found between the two
groups with regard to BMI and age, L2-4BMD and
total body BMD.
The mean BMD of the 2nd to 4th lumbar verte-
brae (L2-4BMD), regional and total body BMD
were measured by DXA using a Hologic QDR
2000 (Waltham, MA, USA). The coefficient of
variation (CV) for DXA for total BMD and soft
tissue mass was 0.5%-1.0% (9).
The regional BMD (g/cm2) was measured in
the head, arms, ribs, thoracic spine, lumbar spine,
pelvis and legs (Figure 1). The regional BMD (g/
cm2) was measured in the head, arms, legs, ribs,
thoracic spine, lumbar spine and pelvis. The hori-
zontal line above the shoulders should be just
below the chin. The vertical lines at the shoulders
should be between the head of the humerus and
scapula at the glenoid fossa. The vertical lines on
either side of the spine should be moved close to
the spine, angled to match the curvature if possi-
ble. The small horizontal line should be approxi-
mately at the level of L1-T12. The horizontal line
above the pelvis should be just above the crest of
Table 1. Comparison of characteristics of alendronate and alfacalcidol groups.
Alendronat group Alfacalcidol group P value
(n=35) (n=57)
Age 65.2±4.0 66.0±4.5 0.3388
BMI (kg/m2) 21.5±2.3 22.3±3.1 0.2233
L2-4 BMD (g/cm2) 0.678±0.082 0.695±0.104 0.427
Total body BMD (g/cm2) 0.824±0.066 0.836±0.064 0.4061
BMI, body mass index ; L2-4 BMD, the mean bone mineral density of the 2nd to 4th lumbar vertebrae
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the ilium. This line can be extended out at the
sides to include soft tissue in the chest and waist.
If at all possible, soft tissue from the trunk should
not be included with the arms. Due to patient size
and placement of the hands, this may not always
be possible. The angled lines below the pelvis
should bisect both femoral necks. The vertical line
between the legs should be adjusted to be be-
tween the feet. The vertical lines lateral to (outside
of) the legs should be adjusted to include as much
of the soft tissue in the thighs as possible.
STATISTICS
Results were expressed as the mean±standard
deviation. Unpaired Student’s t-test was used to
evaluate the differences between the two groups.
A P value of less than 0.05 was considered signifi-
cant.
RESULTS
Fracture
After one-year treatment, 1 of 35 women in the
alendronate group and 4 of 57 patients in the alfa-
calcidol group suffered vertebral fractures.
Regional and total body BMD (Table 2)
Percent change of pre-treatment level of L2-4
BMD and regional BMD of alendronate group
were significantly greater than those of alfacalcidol
Figure 1. Screen display of total and regional BMD in vivo.
Table 2. Comparison of percent change of L2-4 BMD, BMD and BMC between alendronate and alfacalcidol groups.
Alendronate group Alfacalcidol group P value
(n=35) (n=57)
% L2-4 BMD (%) 106.3±4.6 100.7±6.8 < 0.0001
% Lt arm BMD (%) 101.2±4.0 98.7±3.4 0.0019
% Rt arm BMD (%) 100.4±3.4 97.7±3.4 0.0263
% Lt rib BMD (%) 103.2±6.7 98.9±5.5 0.0016
% Rt rib BMD (%) 102.2±4.2 99.6±5.3 0.017
% Thoracic spine BMD (%) 104.2±6.6 98.2±7.0 0.0001
% Lumbar spine BMD (%) 107.1±10.4 100.7±6.9 0.0007
% Pelvis BMD (%) 107.1±10.5 100.6±6.9 0.0013
% Lt leg BMD (%) 100.1±2.6 98.5±3.4 0.015
% Rt leg BMD (%) 100.4±2.2 98.8±3.4 0.0096
% Head BMD (%) 101.3±3.1 101.1±3.5 0.9228
% Total body BMD (%) 101.1±1.8 99.2±2.2 < 0.0001
BMD, bone mineral density ; L2-4 BMD, the mean BMD of the 2nd to 4th lumbar vertebrae.
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group except for BMD of head. In the alendronate
group, percentage change of L2-4BMD, lumbar
spine BMD, thoracic spine BMD and pelvic BMD
of alendronate group were greater than those of
other regional BMD. There was no significant dif-
ference of the percent change of pre-treatment level
of head BMD between the two groups.
L2-4BMD, lumbar spine BMD and thoracic spine
BMD were maintained at respective pre-treatment
levels, whereas other regional BMD were de-
creased following one-year treatment with alfacal-
cidol.
Markers of bone mineral metabolism (Table 3, Table 4)
There were no significant differences of pre-
treatmet levels of markers of bone mineral me-
tabolism between these two groups (Table 3).
Percent change of urinary type I collagen cross-
linked N-telopeptide (NTX) of the alendronate group
was decreased to 55.1±30.5% of the pre-treatment
level. In contrast, percent change of urinary NTX
of alfacalcidol group was increased to 103.3±50.2%
of the pre-treatment level. There was significant
difference between the two groups (p=0.0002).
Percent change of serum alkaline phosphatase
(AP) of alendronate group decreased to 77.4±18.0%
of the pre-treatment level, whereas that of alfacal-
cidol group increased to 106.4±50.9% of the pre-
treatment level, which was significantly different
(p=0.0073). Percent change of serum bone-specific
alkaline phosphatase (BAP) of alendronate group
was decreased to 65.6±21.3% of the pre-treatment
level, whereas that of alfacalcidol group was in-
creased to 104.8±45.3% of the pre-treatment level.
There was significantly difference between the two
groups (p=0.0002) (Table 4).
Table 4. Percent change of markers of bone mineral metabolism.
Alendronate group Alfacalcidol group P value
(n=35) (n=57)
% Urinary NTX (%) 55.1±30.5 103.3±50.2 0.0002
% Serum AP (%) 77.4±18.0 106.4±50.9 0.0073
% Serum BAP (%) 65.6±21.3 104.8±45.3 0.0002
% Serum Ca (%) 98.0±14.6 97.9±9.4 0.2968
% Serum P (%) 93.5±14.6 94.8±10.4 0.7502
AP, alkaline phosphatase ; NTX, type I collagen cross-linked N-telopeptide ; BAP, bone-specific alkaline phosphatase
Table 3. Comparison of markers of bone mineral metabolism before treatment.
Alendronate group Alfacalcidol group P value
(n=35) (n=57)
Urinary NTX 57.0±28.9 45.6±13.5 0.1121
(nMBCE/mMCr)
Serum AP 268.3±97.6 281.4±67.8 0.619
(IU/l)
Serum BAP 36.5±11.9 29.8±14.4 0.0983
(U/l)
Serum Ca 8.9±1.1 8.6±1.5 0.398
(mg/dl)
Serum P 4.0±1.4 4.1±1.5 0.722
(mg/dl)
AP, alkaline phosphatase ; NTX, type I collagen cross-linked N-telopeptide ; BAP, bone-specific alkaline phosphatase
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DISCUSSION
One-year treatment with alendronate increased
L2-4BMD, thoracic spine BMD, lumbar spine BMD
and pelvic BMD, and maintained other regional
BMD. In contrast, one-year treatment with alfacal-
cidol maintained L2-4BMD, lumbar spine BMD,
pelvis BMD and head BMD, and decreased other
regional BMD. Einhorn (10) showed that the rela-
tive content of trabecular bone varied among the
different parts of the skeleton, and that the content
of trabecular bone of vertebra was 66-90%, that of
the hip at the intertrochanteric region was 50%,
that of the hip at the femoral neck was 25%, that of
the distal radius was 25%, that of the mid-radius
was 1%, and that of the femoral shaft was 5%. As
for bone metabolism, the trabecular bone is ap-
proximately eight times as metabolically active as
cortical bones, because the surface of trabecular
bone is larger than that of cortical bone, and the
response to metabolic changes in trabecular bone
is faster than that of cortical bone (11). Therefore,
the great rate of increase in L2-4BMD, thoracic
spine BMD, lumbar spine BMD and pelvis BMD
after one-year treatment of alendronate may be due
to the high content of trabecular bone compared
with other regional bones.
In this study, one-year treatment of alendronate
increased lumbar spine BMD, thoracic spine BMD
and pelvis BMD. Smith showed that BMD was
accounted for approximately 75-80% of the vari-
ance in the bone strength (2). In addition to BMD,
bone quality is also one of important determinants
of bone strength. Alendronate improves trabecular
bone microarchitecture of the ileum (greater bone
volume, trabecular thickness, decrease in trabecu-
lar spacing) (12). Based on these facts, one-year
treatment of alendronate increases bone strength
and prevents vertebral fracture and hip fracture in
osteoporotic patients.
Urinary NTX of the alendronate group were de-
creased, whereas urinary NTX of the alfacalcidol
group was increased. Urinary NTX is one of the
markers of bone resorption. This fact showed that
alendronate inhibits osteoclast-mediated bone re-
sorption. In addition, one-year treatment with alen-
dronate decreased serum BAP, whereas serum
BAP in the alfacalcidol group was increased. Serum
BAP is an index of bone turnover. This suggests
that one-year treatment with alendronate normal-
izes bone turnover in patients with osteoporosis.
Previous studies have shown that combination
therapy of alendronate and calcitriol are more ef-
fective to increase BMD in patients with osteopo-
rosis than monotherapy with either calcitriol or
alendronate (13, 14). Recker et al. (15) showed
that alendronate provides efficacy of bone resorp-
tion as measured by serum BAP and urinary NTX,
and that alendronate with cholecalciferol increases
25-hydroxyvitamin D (25-OH-D), whereas alendro-
nate without cholecalciferol decreases 25-OH-D.
Combination therapy of alfacalcidol and alendro-
nate may be more effective to increase regional
BMD and to reduce risk of osteoporotic fractures.
Further studies are required to clarify the thera-
peutic effects of combination therapy of alfacalci-
dol and alendronate on prophylaxis of osteoporotic
fractures.
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